Who Owns GoodRx?
Updated onExplore the ownership hierarchy of GoodRx. See parent companies, holding structures, and ultimate controllers.
Ownership Chain
GoodRx
American healthcare company operating a free prescription price-comparison website and mobile app that provides pharmacy coupons, telemedicine services, and a paid GoodRx Gold membership for deeper discounts.
Starts at $0
GoodRx appears to be independent with no known parent company.
GoodRx
American healthcare company operating a free prescription price-comparison website and mobile app that provides pharmacy coupons, telemedicine services, and a paid GoodRx Gold membership for deeper discounts.
Starts at $0
GoodRx appears to be independent with no known parent company.
Major Shareholders
GoodRx
Major Shareholders
| Name | Type | Ownership | As of |
|---|---|---|---|
Francisco Partners Management, L.P. Private equity sponsor; through its Francisco Partners IV funds it reported beneficial ownership of about 60.1 million GoodRx shares (primarily Class B shares convertible into Class A), corresponding to roughly 17.7% of total share capital and about 36% of the Class A common stock equivalents, based on March 2025 Schedule 13D/A filings and subsequent institutional-holder summaries. | Institutional | 17.7% | Dec 2025 |
Idea Men, LLC Founder‑affiliated holding company for GoodRx insiders; Simply Wall St’s December 2025 ownership breakdown attributes about 43.2 million shares (~12.7% of total shares) to Idea Men, LLC, making it one of the largest direct shareholders of GoodRx Holdings, Inc. | Corporate | 12.7% | Dec 2025 |
The Vanguard Group, Inc. Large index asset manager; Nasdaq’s Q3‑2025 institutional‑holdings data and other ownership databases show Vanguard entities holding roughly 9.2 million GoodRx shares, which Simply Wall St estimates at about 2.7% of total outstanding shares (a higher percentage if measured against Class A shares only). | Institutional | 2.7% | Dec 2025 |
Douglas Hirsch GoodRx co‑founder and director; Simply Wall St attributes about 5.43 million shares (~1.6% of total shares) held directly in his name as of late 2025, separate from his indirect interest through Idea Men, LLC. | Founder | 1.6% | Dec 2025 |
Trevor Bezdek GoodRx co‑founder and director; Simply Wall St reports approximately 5.39 million shares (~1.59% of total shares) held directly, in addition to his indirect stake via Idea Men, LLC. | Founder | 1.6% | Dec 2025 |
Ameriprise Financial Inc. (incl. Columbia Management Investment Advisers, LLC) Asset‑management group; Q3‑2025 13F‑based data from Nasdaq and ownership summaries show Ameriprise/Columbia entities holding about 3.89 million GoodRx shares, corresponding to roughly 1.1% of total shares. | Institutional | 1.1% | Dec 2025 |
Silver Lake Technology Management, L.L.C. Private‑equity/technology investor; databases of top shareholders list Silver Lake entities with around 3.53 million GoodRx shares (just over 1% of total shares) as of late 2025. | Institutional | 1.0% | Dec 2025 |
Renaissance Technologies LLC Quantitative hedge fund; Q3‑2025 institutional‑ownership data show Renaissance holding roughly 3.47 million shares, about 1.0% of GoodRx’s total outstanding shares. | Institutional | 1.0% | Dec 2025 |
Petrus Trust Company, LTA Investment trust; listed among the largest shareholders with approximately 3.10 million GoodRx shares, or about 0.9% of total shares, in late‑2025 ownership summaries. | Institutional | 0.9% | Dec 2025 |
Dimensional Fund Advisors LP Institutional asset manager; Q3‑2025 filings aggregated by Nasdaq and Simply Wall St indicate holdings of roughly 2.50 million shares (~0.7% of total shares). | Institutional | 0.7% | Dec 2025 |
LSV Asset Management Value‑oriented institutional manager; shown with about 2.35 million GoodRx shares (~0.7% of total) in late‑2025 institutional‑ownership datasets. | Institutional | 0.7% | Dec 2025 |
BlackRock, Inc. Global asset manager; Q3‑2025 institutional‑holder reports list BlackRock with just under 2.0 million GoodRx shares, about 0.6% of total shares outstanding. | Institutional | 0.6% | Dec 2025 |
Get Started
Your ultimate competitive playbook
You just found your top competitors. Now let's map your whole landscape and show you how to stand out.
Competitive Landscape Report
Built for small teams who can't hire a full-time analyst.
$129 $260 one-time payment
Generated in minutes, no subscription.
Instead of guessing what to do about your competitors, get a done-for-you intelligence report
Competitor Map
Direct, indirect, and alternative competitors mapped across your market
Positioning Analysis
How each competitor positions, their ICP, and key differentiators
Feature & Pricing Matrix
Side-by-side comparison of features, pricing, and packaging strategies
Growth Channel Analysis
SEO, paid ads, content, and social strategies across the landscape
Reputation & Social Proof
Ratings, reviews, and sentiment analysis across all competitors
90-Day Action Plan
Specific tactics to differentiate and win more deals in the next 3 months